Actively Recruiting
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
Led by Novartis Pharmaceuticals · Updated on 2026-04-01
200
Participants Needed
1
Research Sites
150 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, non-interventional real-world study designed to assess the efficacy and safety of asciminib in patients with newly diagnosed CML.The study uses a prospective data collection design to gather baseline, pre- and post-treatment, and long-term follow-up data, enabling a comprehensive assessment of asciminib's clinical benefits.
CONDITIONS
Official Title
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older at the time of informed consent signing
- Newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase within 3 months before enrollment
- Diagnosis documentation must include type and quantitative level of BCR-ABL1 transcript
- Prior treatment with tyrosine kinase inhibitors for no more than 2 weeks
- Prior treatment with non-tyrosine kinase inhibitor regimens, including interferon and hydroxyurea, allowed
- Scheduled to start treatment with asciminib within 14 days of informed consent signing
- Signed informed consent form
You will not qualify if you...
- Previous diagnosis of accelerated phase or blast crisis of chronic myeloid leukemia
- Currently participating in an interventional clinical study for chronic myeloid leukemia
- Having rare or atypical transcript types that cannot be standardized internationally
- Women who are pregnant, lactating, or planning to become pregnant during the study
- Having other concurrent malignancies such as carcinoma or malignant neoplasm
- Other conditions deemed unsuitable for the study by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Novartis Investigative Site
Wuhan, Hubei, China, 430022
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here